


# Ovarian cancer




Average chemotherapy use by stage at diagnosis (2012–2017)




## Australia




## Canada



## Norway



## UK



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: England (17%), NI (12%), Scotland (13%), Wales (28%), BC (34%), Ontario (33%).

Figures from Manitoba and Nova Scotia were rounded to suppress small numbers


# Ovarian cancer




Average chemotherapy use by stage at diagnosis (2012–2017):  
stages 1–2 or local and regional




## Australia




## Canada



## Norway



## UK



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: England (17%), Northern Ireland (12%), Scotland (13%), Wales (28%), British Columbia (34%), Ontario (33%).

Figures from Manitoba and Nova Scotia were rounded to suppress small numbers

'Overall average' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.

# Ovarian cancer




Average chemotherapy use by stage at diagnosis (2012–2017):  
stages 3–4 or distant




## Australia

New South Wales




## Canada

Ontario  
British Columbia  
Alberta  
Manitoba  
Nova Scotia




## Norway

Norway



## UK

Scotland  
Wales  
England  
Northern Ireland



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: England (17%), Northern Ireland (12%), Scotland (13%), Wales (28%), British Columbia (34%), Ontario (33%).

Figures from Manitoba and Nova Scotia were rounded to suppress small numbers



'Overall average' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.

# Ovarian cancer

Average chemotherapy use by TNM stage at diagnosis (2012–2017)



UK



\*Fewer than 100 patients



Some jurisdictions had a large % of missing stage data which could introduce bias: England (17%), Northern Ireland (12%), Scotland (13%), Wales (28%).

# Ovarian cancer

Average chemotherapy use by TNM stage at diagnosis (2012–2017)



Canada



\*Fewer than 100 patients

Some jurisdictions had a large % of missing stage data which could introduce bias: British Columbia (34%), Ontario (33%).

Figures from Manitoba and Nova Scotia were rounded to suppress small numbers

# Ovarian cancer


Average chemotherapy use by SEER stage at diagnosis (2012–2017)



Australia



Norway



\*Fewer than 100 patients